絞り込み

16287

広告

679件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Quantitative tyrosine phosphoproteomics of EGFR tyrosine kinase inhibitor-treated lung adenocarcinoma cells reveals potential novel biomarkers of therapeutic response.

EGFR inhibition in NSCLC: New findings…. and opened questions?

A new solvate of afatinib, a specific inhibitor of the ErbB family of tyrosine kinases.

Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report.

Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.

Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib.

Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.

Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.

Sub-Clonal Therapy by two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-mutated Lung Cancer.

Investigational Therapies for Squamous Cell Lung Cancer: From Animal Studies to Phase II Trials.

The safety of second-line treatment options for non-small cell lung cancer.

B-Myb Induces APOBEC3B Expression Leading to Somatic Mutation in Multiple Cancers.

An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.

Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.

Afatinib ameliorates osteoclast differentiation and function through downregulation of RANK signaling pathways.

Emerging challenges of advanced squamous cell lung cancer.

Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.

[Precision first-line therapy for advanced non-small-cell lung cancer patients harboring EGFR mutation].

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります